ACVR1 and diffuse intrinsic pontine glioma: Importantly, the ALK2 inhibitors LDN-193189, LDN-212854 and LDN-214117 have all demonstrated suitable brain penetration, tolerability and pharmacokinetic properties for use in orthotopic in vivo models of DIPG [55,56].